How are these compounds
scientifically different?
Compare mechanisms, targets, research profiles and pharmacokinetics for up to 4 compounds side by side. This maps what is scientifically known — it does not tell you which compound to choose.
This is a scientific comparison, not a recommendation. It does not answer "which should I take?" — for potential combination-specific considerations, see the Interaction Checker; for regulatory/clinical-development history, see the Research Status Explorer.
Target & Mechanism Comparison
Primary molecular targets for each selected compound, drawn directly from each compound's structured scientific record. Not every compound has a single conventional receptor target — where that's the case, its differentiating mechanism is noted below instead.
← Scroll to see all compounds →
| Target | Melanotan II | PT-141 |
|---|---|---|
| ✓ | ✓ |
Pathway Map
This is a schematic, not a claim that every step shown has been directly demonstrated for each compound. The receptor immediately after each compound is its direct, structurally-confirmed target; anything shown beyond that receptor represents the broader documented signalling axis for that receptor family in general, not a compound-specific downstream finding.
What These Compounds Share
Key Differences
Compound Detail
Melanotan II
Simplified for general understanding. Switch to "Full science" above for the complete research-level detail, targets, pharmacokinetics and sources.
Synthetic cyclic α-MSH analogue · Synthetic analogue
Also known as: MT-II
Tap a target above for a plain-language explanation.
Not an approved or established use. These are active or emerging research directions found in the literature, shown for informational context only — not a claim that this compound is approved, effective, or safe for these purposes.
View Research Sources (3) →
Double-blind, placebo-controlled crossover, RigiScan-monitored over 6 hours. Clinically apparent erections in 8/10 men on Melanotan II. Mean tip-rigidity >80% duration: 38.0 min (MT-II) vs 3.0 min (placebo), P=0.0045.
Supports: experimental_research
Double-blind, placebo-controlled crossover, RigiScan-monitored. Erection without sexual stimulation in 17/20 men (mean 41 min tip rigidity >80%). Increased sexual desire reported after 68% of MT-II doses vs 19% of placebo doses (P<0.01). Severe nausea in 12.9% at 0.025 mg/kg.
Supports: experimental_research
Single-blind, alternating-day, placebo-controlled Phase I safety/pigmentation study. Mild nausea and stretching/yawning correlating with spontaneous erections; increased pigmentation of face/upper body/buttock in 2 of 3 subjects. Recommended future Phase I dose: 0.025 mg/kg/day.
Supports: mechanism_summary, short_description
PT-141
Simplified for general understanding. Switch to "Full science" above for the complete research-level detail, targets, pharmacokinetics and sources.
Cyclic heptapeptide · 7 amino acids · Synthetic analogue
Also known as: Bremelanotide
Tap a target above for a plain-language explanation.
FDA prescribing information (Vyleesi/bremelanotide): median Tmax ~1 hour, terminal half-life ~2.7 hours, subcutaneous bioavailability ~100%, plasma protein binding ~21%.
Not an approved or established use. These are active or emerging research directions found in the literature, shown for informational context only — not a claim that this compound is approved, effective, or safe for these purposes.
View Research Sources (1) →
Median Tmax ~1h, terminal half-life ~2.7h, SC bioavailability ~100%, protein binding ~21%. Applies to bremelanotide specifically.
Supports: human_half_life, research_routes
Common Research Comparisons
Frequently studied groupings — not recommendations.
Browse more compounds
5-Amino-1MQ
NNMT inhibitor
BPC-157
Gastric pentadecapeptide
Cagrilintide
Long-acting amylin analogue
CJC-1295
Modified GHRH analogue
DSIP
Neuropeptide
Epithalon
Synthetic tetrapeptide
GHK-Cu
Copper-binding tripeptide
GHRP-2
GH-releasing peptide / GH secretagogue
Glutathione
Endogenous antioxidant tripeptide
HCG
Glycoprotein hormone
IGF-1 LR3
IGF-1 receptor agonist (engineered analogue)
Ipamorelin
GH secretagogue
Kisspeptin-10
Kisspeptin fragment
KPV
α-MSH-derived tripeptide
Melanotan I
α-MSH analogue
Melanotan II
Cyclic melanocortin agonist
MOTS-c
Mitochondrial-derived peptide
NAD+
Cellular redox cofactor
PT-141
Cyclic melanocortin receptor agonist
Retatrutide
Triple receptor agonist
rHGH (Somatropin)
Growth hormone receptor agonist
Selank
Synthetic tuftsin analogue
Semaglutide
GLP-1 receptor agonist
Semax
Synthetic ACTH-fragment analogue
Sermorelin
GHRH fragment analogue
SS-31
Mitochondria-targeting tetrapeptide
Tesamorelin
Stabilised GHRH analogue
Thymosin Alpha-1
Thymic peptide
Thymosin Beta-4 (TB-4)
Thymosin Beta-4
Tirzepatide
Dual incretin receptor agonist